Onchocerciasis — A potential revolution in its treatment
✍ Scribed by Hugh R. Taylor
- Book ID
- 104636563
- Publisher
- Springer Netherlands
- Year
- 1987
- Tongue
- English
- Weight
- 239 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0165-5701
No coin nor oath required. For personal study only.
✦ Synopsis
Onchocerciasis is a major blinding disease affecting at least 28 million people in Africa and Latin America. Although a large-scale vector control program has been highly successful in limiting transmission of infection in West Africa, there has not been a satisfactory form of treatment available for those already infected or those living in other areas. Despite the fact that two drugs, diethylcarbamazine and suramin, are active against the filarial parasite that causes onchocerciasis, their use is severely limited by their toxicity and the reaction they induce. A newly developed drug, ivermectin, appears to offer a major revolution in the treatment of onchocerciasis. In a series of clinical trials, ivermectin has been shown to be an extremely effective microfilaricide which induces only minimal side effects. Ivermectin is given as a single oral dose which can be repeated on an annual basis. In view of its safety and efficacy and its ease of administration, it seems likely that ivermectin will be suitable for use in mass chemotherapy programs against onchocerciasis.
📜 SIMILAR VOLUMES
A group of 87 onchocerciasis patients from a hyperendemic area without vector control was treated with a single dose of 150 txg/kg ivermectin. A second, third and fourth dose was administered 5, 12 and 17 months later to 44, 35 and 25 patients. Skin snip loads reduced substantially following each co